Global Tuberculosis (TB) Diagnostics Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Tuberculosis (TB) Diagnostics market size will reach US$ 4099 million by 2031.
Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. The historical term "consumption" came about due to the weight loss. Infection of other organs can cause a wide range of symptoms.
The global TB diagnostics market is being propelled by the urgent need to improve disease detection and control in response to the persistent burden of tuberculosis, particularly in high-prevalence regions. Efforts to reach WHO’s End TB goals have elevated funding for TB programs, driving the rollout of advanced diagnostic tools like molecular assays , X‑ray based screening solutions with AI assistance, and point-of-care tests. Furthermore, increasing integration of TB screening within broader healthcare initiatives—such as universal healthcare coverage and integrated respiratory disease programs—has expanded testing capacity. The push to screen high-risk populations, including people living with HIV, healthcare workers, migrants, and prison inmates, has also increased demand for rapid, accurate, and decentralized diagnostic methods capable of delivering same-day results and guiding treatment decisions.
Despite significant advancements in TB diagnostics, substantial barriers continue to hinder market expansion. One major challenge is inconsistent access to cutting-edge diagnostic tools in low- and middle-income countries, where infrastructure remains limited and centralized laboratory systems struggle to support widespread deployment. Additionally, the cost of advanced molecular and imaging technologies remains a deterrent, particularly when factoring in expenses for equipment maintenance, consumables, and the specialized training required for healthcare personnel. The regulatory and logistical complexities involved in distributing diagnostic platforms—especially in remote rural areas—also slow down adoption. Finally, the co-existence of disparate diagnostic algorithms across countries, combined with variable healthcare funding and weak supply chain systems, continues to limit consistent implementation of guideline-compliant testing and undermines efforts to significantly reduce TB incidence.
Global Tuberculosis (TB) Diagnostics key players include Danaher, Roche, Thermo Fisher Scientific, BD, Abbott, etc. Global top five manufacturers hold a share about 33%. APAC is the largest market, with a share over 40%, followed by Americas and Europe, both have a share about 40 percent.
LPI (LP Information)' newest research report, the “Tuberculosis (TB) Diagnostics Industry Forecast” looks at past sales and reviews total world Tuberculosis (TB) Diagnostics sales in 2024, providing a comprehensive analysis by region and market sector of projected Tuberculosis (TB) Diagnostics sales for 2025 through 2031. With Tuberculosis (TB) Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tuberculosis (TB) Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Tuberculosis (TB) Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Tuberculosis (TB) Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tuberculosis (TB) Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tuberculosis (TB) Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tuberculosis (TB) Diagnostics.
This report presents a comprehensive overview, market shares, and growth opportunities of Tuberculosis (TB) Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Culture-Based Diagnostics
Sputum Smear Microscopy
Rapid Molecular Diagnostics
Others
Segmentation by Application:
Diagnostic Laboratories
Hospitals
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Danaher
Roche
Thermo Fisher Scientific
BD
Abbott
Hologic
Qiagen
BioMerieux
Hain Lifescience
Oxford Immunotec
Please note: The report will take approximately 2 business days to prepare and deliver.
Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. The historical term "consumption" came about due to the weight loss. Infection of other organs can cause a wide range of symptoms.
The global TB diagnostics market is being propelled by the urgent need to improve disease detection and control in response to the persistent burden of tuberculosis, particularly in high-prevalence regions. Efforts to reach WHO’s End TB goals have elevated funding for TB programs, driving the rollout of advanced diagnostic tools like molecular assays , X‑ray based screening solutions with AI assistance, and point-of-care tests. Furthermore, increasing integration of TB screening within broader healthcare initiatives—such as universal healthcare coverage and integrated respiratory disease programs—has expanded testing capacity. The push to screen high-risk populations, including people living with HIV, healthcare workers, migrants, and prison inmates, has also increased demand for rapid, accurate, and decentralized diagnostic methods capable of delivering same-day results and guiding treatment decisions.
Despite significant advancements in TB diagnostics, substantial barriers continue to hinder market expansion. One major challenge is inconsistent access to cutting-edge diagnostic tools in low- and middle-income countries, where infrastructure remains limited and centralized laboratory systems struggle to support widespread deployment. Additionally, the cost of advanced molecular and imaging technologies remains a deterrent, particularly when factoring in expenses for equipment maintenance, consumables, and the specialized training required for healthcare personnel. The regulatory and logistical complexities involved in distributing diagnostic platforms—especially in remote rural areas—also slow down adoption. Finally, the co-existence of disparate diagnostic algorithms across countries, combined with variable healthcare funding and weak supply chain systems, continues to limit consistent implementation of guideline-compliant testing and undermines efforts to significantly reduce TB incidence.
Global Tuberculosis (TB) Diagnostics key players include Danaher, Roche, Thermo Fisher Scientific, BD, Abbott, etc. Global top five manufacturers hold a share about 33%. APAC is the largest market, with a share over 40%, followed by Americas and Europe, both have a share about 40 percent.
LPI (LP Information)' newest research report, the “Tuberculosis (TB) Diagnostics Industry Forecast” looks at past sales and reviews total world Tuberculosis (TB) Diagnostics sales in 2024, providing a comprehensive analysis by region and market sector of projected Tuberculosis (TB) Diagnostics sales for 2025 through 2031. With Tuberculosis (TB) Diagnostics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tuberculosis (TB) Diagnostics industry.
This Insight Report provides a comprehensive analysis of the global Tuberculosis (TB) Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Tuberculosis (TB) Diagnostics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tuberculosis (TB) Diagnostics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tuberculosis (TB) Diagnostics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tuberculosis (TB) Diagnostics.
This report presents a comprehensive overview, market shares, and growth opportunities of Tuberculosis (TB) Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Culture-Based Diagnostics
Sputum Smear Microscopy
Rapid Molecular Diagnostics
Others
Segmentation by Application:
Diagnostic Laboratories
Hospitals
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Danaher
Roche
Thermo Fisher Scientific
BD
Abbott
Hologic
Qiagen
BioMerieux
Hain Lifescience
Oxford Immunotec
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
92 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Tuberculosis (TB) Diagnostics Market Size by Player
- 4 Tuberculosis (TB) Diagnostics by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Tuberculosis (TB) Diagnostics Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
